These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 21719531

  • 1. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C, Magnussen H, LaForce C, Owen R, Kramer B.
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 3. [Indacaterol--a new hope for maximising bronchodilation?].
    Mihălţan F.
    Pneumologia; 2011 Dec; 60(1):21-5. PubMed ID: 21548196
    [Abstract] [Full Text] [Related]

  • 4. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [Abstract] [Full Text] [Related]

  • 6. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C, Aumann J, de Teresa Parreño L, Iqbal A, Young D, Owen R, Higgins M, Kramer B, INTEGRAL Study Investigators.
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [Abstract] [Full Text] [Related]

  • 7. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
    Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S.
    Pulm Pharmacol Ther; 2009 Dec; 22(6):492-6. PubMed ID: 19465142
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, Indacaterol Asian COPD Study Investigators.
    Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
    Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP.
    Value Health; 2012 May; 15(3):524-33. PubMed ID: 22583463
    [Abstract] [Full Text] [Related]

  • 10. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 11. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
    Beeh KM, Wagner F, Khindri S, Drollmann AF.
    COPD; 2011 Oct 15; 8(5):340-5. PubMed ID: 21793716
    [Abstract] [Full Text] [Related]

  • 12. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
    Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B, INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators.
    Eur Respir J; 2011 Feb 15; 37(2):273-9. PubMed ID: 20693243
    [Abstract] [Full Text] [Related]

  • 13. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M.
    Respir Med; 2008 Jul 15; 102(7):1033-44. PubMed ID: 18479895
    [Abstract] [Full Text] [Related]

  • 14. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
    Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D.
    Pulm Pharmacol Ther; 2010 Jun 15; 23(3):165-71. PubMed ID: 20080201
    [Abstract] [Full Text] [Related]

  • 15. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.
    Pulm Pharmacol Ther; 2007 Jun 15; 20(6):740-9. PubMed ID: 17088091
    [Abstract] [Full Text] [Related]

  • 16. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
    Price D, Gray A, Gale R, Asukai Y, Mungapen L, Lloyd A, Peters L, Neidhardt K, Gantner T.
    Respir Med; 2011 Nov 15; 105(11):1635-47. PubMed ID: 21764277
    [Abstract] [Full Text] [Related]

  • 17. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ, Keating GM.
    Treat Respir Med; 2004 Nov 15; 3(4):247-68. PubMed ID: 15350163
    [Abstract] [Full Text] [Related]

  • 18. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
    Beeh KM, Beier J.
    Adv Ther; 2009 Jul 15; 26(7):691-9. PubMed ID: 19609496
    [Abstract] [Full Text] [Related]

  • 19. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
    Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG.
    Respir Med; 2013 Jun 15; 107(6):848-53. PubMed ID: 23490225
    [Abstract] [Full Text] [Related]

  • 20. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM, Williams J.
    Ther Adv Respir Dis; 2013 Feb 15; 7(1):25-37. PubMed ID: 23296242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.